Literature DB >> 8871762

Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases?

L Adorini1, J C Guéry, S Trembleau.   

Abstract

Differentiated T cells produce a restricted set of lymphokines, allowing their subdivision into two major subsets: Th1 and Th2 cells. This has lead to a new paradigm for immunoregulation based on the Th1/Th2 dichotomy. A strict compartmentalization of T cells into Th1 and Th2 is clearly an oversimplification: regulatory and effector mechanisms in the immune system encompass much more than Th1 and Th2 cells. This oversimplification is nevertheless useful to carry out experiments designed to test the paradigm. Based on results obtained in different experimental models of autoimmune diseases, the subdivision of T cells into Th1 and Th2 subsets has been extended to suggest that Th1 cells contribute to the pathogenesis of several organ-specific autoimmune diseases, whereas Th2 cells may inhibit disease development. Although more slowly and maybe less clearly, a similar dichotomy is starting to emerge in human autoimmune diseases. It will soon be possible to formally test immunointervention based on Th1/Th2 cell manipulation in clinical situations: the tools and a conceptual frame are already available. In this review we will examine two key factors affecting the Th1/Th2 balance: antigen and the role of cytokines influencing the development of Th1 and Th2 cells. The rational manipulation of these two variables may ultimately lead to an effective control of Th1 and Th2 cells potentially able to alter the natural course of human autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871762     DOI: 10.3109/08916939608995329

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  13 in total

1.  Cytokine profile in the liver of primary biliary cirrhosis.

Authors:  T Nagano; K Yamamoto; S Matsumoto; R Okamoto; M Tagashira; N Ibuki; S Matsumura; K Yabushita; N Okano; T Tsuji
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

2.  Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro.

Authors:  K Schroecksnadel; C Winkler; B Wirleitner; H Schennach; D Fuchs
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

3.  Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.

Authors:  Yi Chen; Claire L Langrish; Brent McKenzie; Barbara Joyce-Shaikh; Jason S Stumhofer; Terrill McClanahan; Wendy Blumenschein; Tatyana Churakovsa; Justin Low; Leonard Presta; Christopher A Hunter; Robert A Kastelein; Daniel J Cua
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

4.  Complex pattern of Th1 and Th2 activation with a preferential increase of autoreactive Th1 cells in BALB/c mice with proteoglycan (aggrecan)-induced arthritis.

Authors:  K Holló; T T Glant; M Garzó; A Finnegan; K Mikecz; E Buzás
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

5.  Combined cyclosporin-A /prednisone therapy of patients with active uveitis suppresses IFN-gamma production and the function of dendritic cells.

Authors:  M A Frassanito; R Dammacco; T Fusaro; A Cusmai; S Guerriero; C Sborgia
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 6.  Using EAE to better understand principles of immune function and autoimmune pathology.

Authors:  Manu Rangachari; Vijay K Kuchroo
Journal:  J Autoimmun       Date:  2013-07-09       Impact factor: 7.094

7.  Suppression of ongoing experimental arthritis by a chinese herbal formula (huo-luo-xiao-ling dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation.

Authors:  Ying-Hua Yang; Rajesh Rajaiah; David Y-W Lee; Zhongze Ma; Hua Yu; Harry H S Fong; Lixing Lao; Brian M Berman; Kamal D Moudgil
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-19       Impact factor: 2.629

Review 8.  Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.

Authors:  Shyi-Jou Chen; Yen-Ling Wang; Hueng-Chuen Fan; Wen-Tsung Lo; Chih-Chien Wang; Huey-Kang Sytwu
Journal:  Clin Dev Immunol       Date:  2011-12-06

9.  Attenuation of murine antigen-induced arthritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer and activator of transcription-1 (STAT-1).

Authors:  Marion Hückel; Uta Schurigt; Andreas H Wagner; Renate Stöckigt; Peter K Petrow; Klaus Thoss; Mieczyslaw Gajda; Steffen Henzgen; Markus Hecker; Rolf Bräuer
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 10.  Multiple sclerosis: the role of cytokines in pathogenesis and in therapies.

Authors:  Amedeo Amedei; Domenico Prisco; Mario Milco D'Elios
Journal:  Int J Mol Sci       Date:  2012-10-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.